Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Novo Nordisk A/S — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.82 (market cap $2.98B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 55.5× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and Novo Nordisk A/S pays a 4.71% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and Novo Nordisk A/S for 116 Days on average.
| FNGU | NVO | |
|---|---|---|
Market Cap | $2.98B | $165.31B |
Volume | 4,682,352 | 11,432,838 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $63.98 |
52-Week Low | $13.73 | $35.29 |
Typical Hold Time | 19 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $36.62, down 1.56% today. Technical indicators show a bullish trend with strong moving average support, though oscillators remain neutral. The ETN provides triple exposure to tech giants like Nvidia, Meta, and Apple, but carries significant volatility risks as highlighted by recent analysis showing an 87% decline during previous tech sector downturns.
The outlook remains highly speculative given the leveraged structure. While bullish technicals suggest potential upside if tech stocks continue performing, the extreme volatility and historical drawdowns present substantial risk. Investors should weigh the amplified returns against the possibility of rapid losses during market corrections.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
